Form 4 for ATRA Atara Biotherapeutics, Inc.
Accepted 2023-03-06 00:00:00 ET · period of report 2023-03-02 · accession 0001567619-23-004537 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-06 | 2023-03-02 | ATRA | Dupont Jakob | EVP, Head of R, D | S - Sale | $3.63 | -5,074 | 290.8K | -2% | -$18.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-02 | S | D | 5,074 | $3.63 | 290,794 | D | — | — | (F2) The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2023 and March 3, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. |